The John Hopkins University School of Medicine
Welcome,         Profile    Billing    Logout  
 8 Trials 
13 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Koehne, Guenther
DALY II USA, NCT04792489: / MB-CART2019.1 for DLBCL

Recruiting
2
110
US
zamtocabtagene autoleucel (MB-CART2019.1), Cyclophosphamide, Fludarabine, Bendamustine
Miltenyi Biomedicine GmbH
Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma, High Grade B-cell Lymphoma (HGBCL), Primary Mediastinal B-cell Lymphoma (PMBCL), Transformed Lymphoma, Central Nervous System Lymphoma
12/24
12/26
NCT04684979: Transplantation of Hematopoietic Stem Cells From HLA-compatible Donors in Patients With B-Cell Lymphoid Malignancies

Withdrawn
2
90
US
Hematopoietic Stem Cells from HLA-compatible Related, Hematopoietic Stem Cells from HLA Unrelated
Baptist Health South Florida
B-Cell Lymphoid Malignancies, Hematologic Malignancy, Non-Hodgkin Lymphoma
03/26
03/27
NCT05565105: CD34+ Transplants for Leukemia and Lymphoma

Not yet recruiting
2
100
US
Total Body Irradiation (TBI), Thiotepa, Thioplex, Cyclophosphamide, Cytoxan, Busulfan, Busulfex, Melphalan, Alkeran, Fludarabine, Fludara
Guenther Koehne
Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute
03/32
03/32
NCT05617625: CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome

Suspended
2
50
US
Busulfan, Busulfex, Melphalan, Alkeran, Fludarabine, Fludara, CliniMACS CD34+ enriched, T-cell depleted peripheral blood stem cell (PBSC)
Guenther Koehne
Myelodysplastic Syndromes, Graft Vs Host Disease, Graft-versus-host-disease
03/32
03/32
IMAGINE, NCT05138458: A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL

Suspended
1/2
40
US
MT-101, MT-101 + Conditioning (Lymphodepleting) Chemotherapy
Myeloid Therapeutics
Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides, Adoptive Cellular Immunotherapy, Cell Therapy
11/24
10/25
VBP101, NCT04849910: Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS

Recruiting
1/2
24
Canada, US
VOR33, Mylotarg, gemtuzumab ozogamicin
Vor Biopharma
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
02/25
01/27
VBP301, NCT05984199: Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant

Recruiting
1/2
24
US
VCAR33
Vor Biopharma
Leukemia, Myeloid, Acute
12/24
11/26
NCT04982354: Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia

Withdrawn
1/2
20
US
CPX-351, Midostaurin, Rydapt, Busulfan, Myleran, Melphalan, Alkeran, Fludarabine, Fludara, CD34+ selected allogeneic stem cell transplant from an HLA-compatible donor
Guenther Koehne, Jazz Pharmaceuticals
Acute Myeloid Leukemia
08/31
08/32
FRIDA, NCT05546580: Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)

Checkmark First-patient-in of FRIDA trial in combination with gilteritinib for r/r AML
Nov 2022 - Nov 2022: First-patient-in of FRIDA trial in combination with gilteritinib for r/r AML
Recruiting
1
50
US
Iadademstat, ORY-1001, RO7051790, Gilteritinib Oral Tablet, XOSPATA®
Oryzon Genomics S.A.
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
11/25
11/25
iinnovate-2, NCT05556616 / 2022-001418-20: A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma

Completed
1
15
Europe, US, RoW
Modakafusp alfa, TAK-573, Lenalidomide, Bortezomib, Carfilzomib, Daratumumab, Pomalidomide
Takeda, Takeda Development Center Americas, Inc.
Multiple Myeloma
06/24
06/24
NCT05350163: T-cell Receptor α/β Depleted Donor Lymphocyte Infusion

Terminated
1
11
US
T-cell Receptor α/β Depleted Donor Lymphocyte Infusions
Guenther Koehne
Lymphoid Leukemia, Acute, Myeloid Malignancy, Plasma Cell Tumor
09/23
09/23
NCT05309733: A Long-term Follow-up Study of Patients Who Received VOR33

Recruiting
N/A
36
Canada, US
VOR33
Vor Biopharma
Leukemia, Myeloid, Acute
01/40
01/40
Ambiender, Alexander J
FRIDA, NCT05546580: Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)

Checkmark First-patient-in of FRIDA trial in combination with gilteritinib for r/r AML
Nov 2022 - Nov 2022: First-patient-in of FRIDA trial in combination with gilteritinib for r/r AML
Recruiting
1
50
US
Iadademstat, ORY-1001, RO7051790, Gilteritinib Oral Tablet, XOSPATA®
Oryzon Genomics S.A.
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
11/25
11/25

Download Options